Keywords

• Reliable quality 62253-63-8
• sheep placenta Extract powder Epidermal Growth Factor EGF in bulk supply
• 62253-63-8 sheep placenta Extract

Quick Details

• ProName: Reliable quality 62253-63-8 sheep plac...
• CasNo: 62253-63-8
• Molecular Formula: C270H401N73O83S7
• Appearance: light brown color
• Application: Cosmetics Raw Materials
• DeliveryTime: 7-9
• PackAge: 1kg with double plastic container insi...
• Port: Shanghai
• ProductionCapacity: 100000 Kilogram/Year
• Purity: 98%
• Storage: Stored in a clean, cool, dry area; kee...
• Transportation: Express, air, sea
• LimitNum: 1000 Kilogram
• Heavy Metal: ＜5ppm
• Limited Quantity: 100KG
• Valid Period: 2 Years
• Product Name: Sheep Placenta Extract Powder
• Function: pharmaceutical factories food additive...
• Main Ingredient: Sheep Placenta Extract Powder
• Certificate: COA
• Type: Sheep Placenta
• Place of Origin: Shaanxi， China
• Dosage Form: Powder
• Appearance: light brown
• Grade: Food $ Medical Grade
• Shelf Life: 2 Years

Superiority

Reliable quality 62253-63-8 sheep placenta Extract powder Epidermal Growth Factor EGF in bulk supply 62253-63-8 sheep placenta Extract

Dataintelo published a new report titled “Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market research report which is segmented by Types ( Liquid, Powder), By Applications ( EGF Cream, EGF Lotion, EGF Mask, Other), By Players/Companies Pavay, Radiant, BIO-FD&C, LipoTrue, BIOEFFECT”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

An ophthalmic formulation of epidermal growth factor (urogastrone) has been launched for stimulation of healing of the corneal epithelium following various corneal diseases.

Recombinant human epidermal growth factor has the same structure as the human epidermal growth factor. EGF binds to epidermal growth factor receptor (EGFR) and stimulates cell growth and proliferation. Recombinant human epidermal growth factor is approved for the treatment of diabetic foot ulcers.

Details

According to this latest study, the 2020 growth of Epidermal Growth Factor (EGF) (CAS 62253-63-8) will have significant change from previous year. By the most conservative estimates of global Epidermal Growth Factor (EGF) (CAS 62253-63-8) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 118.2 million in 2019. Over the next five years the Epidermal Growth Factor (EGF) (CAS 62253-63-8) market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 148.7 million by 2025.

EGF is a highly efficient cell division factor with many other biological effects, which mainly includes: 
1. stimulating the growth and proliferation of skin, cornea and tracheal epithelium tissue in vivo. 
2. Accelerating the healing process of epidermis damage on skin, cornea, etc. 
3. Repressing the gastric acid excretion.
4. Accelerating the proliferation of epithelial cells in human and animals. 
5. Facilitating the biosynthesis of protein, RNA, DNA as well as metabolic activity in epidermal cells.